Trial Profile
A retrospective study to evaluate efficacy of switching therapy to aflibercept in patients with central retinal vein occlusion who respond insufficiently to intravitreal ranibizumab and/or bevacizumab therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Central retinal vein occlusion
- Focus Therapeutic Use
- 11 May 2016 New trial record